Related Experiment Video
Updated: Mar 16, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
11.1K
Summary
Brentuximab vedotin, a CD30-targeting antibody-drug conjugate, achieved complete response in 34 patients with relapsed or refractory classic Hodgkin lymphoma. Long-term survival data show 13 patients remain in remission five years later.
Area of Science:
- Oncology
- Pharmacology
Background:
- Classic Hodgkin lymphoma (cHL) is a hematologic malignancy.
- Relapsed or refractory disease presents significant treatment challenges.
Purpose of the Study:
- To evaluate the long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory classic Hodgkin lymphoma.
Main Methods:
- Phase II clinical trial.
- Treatment with brentuximab vedotin, a CD30-targeting antibody-drug conjugate.
Main Results:
- A complete response was observed in 34 patients.
- Of these, 13 patients maintained remission at the 5-year follow-up mark.
Conclusions:
- Brentuximab vedotin demonstrates durable efficacy in a subset of patients with relapsed or refractory classic Hodgkin lymphoma.
- Long-term remission is achievable with this targeted therapy.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K